Planar Imaging

Abstract: Purpose: To examine a new way of body diffusion weighted imaging (DWI) using the short TI inversion recovery-echo planar imaging (STIR-EPI) sequence and free breathing scanning (diffusion weighted whole body imaging with background body signal suppression; DWIBS) to obtain three-dimensional displays. Materials and Methods: 1) Apparent contrast-to-noise ratios (AppCNR) between lymph nodes and surrounding fat tissue were compared in three types of DWI with and without breathholding, with variable lengths of scan time and slice thickness. 2) The STIR-EPI sequence and spin echo-echo planar imaging (SE-EPI) sequence with chemical shift selective (CHESS) pulse were compared in terms of their degree of fat suppression. 3) Eleven patients with neck, chest, and abdominal malignancy were scanned with DWIBS for evaluation of feasibility. Whole body imaging was done in a later stage of the study using the peripheral vascular coil. Results: The AppCNR of 8 mm slice thickness images reconstructed from 4 mm slice thickness source images obtained in a free breathing scan of 430 sec were much better than 9 mm slice thickness breath-hold scans obtained in 25 sec. High resolution multi-planar reformat (MPR) and maximum intensity projection (MIP) images could be made from the data set of 4 mm slice thickness images. Fat suppression was much better in the STIR-EPI sequence than SEEPI with CHESS pulse. The feasibility of DWIBS was showed in clinical scans of 11 patients. Whole body images were successfully obtained with adequate fat suppression. Conclusion: Three-dimensional DWIBS can be obtained with this technique, which may allow us to screen for malignancies in the whole body.

Abstract: Fluorescence sampling of cellular function is widely used in all aspects of biology, allowing the visualization of cellular and sub-cellular biological processes with spatial resolutions in the range from nanometers up to centimeters. Imaging of fluorescence in vivo has become the most commonly used radiological tool in all pre-clinical work. In the last decade, full-body pre-clinical imaging systems have emerged with a wide range of utilities and niche application areas. The range of fluorescent probes that can be excited in the visible to near-infrared part of the electromagnetic spectrum continues to expand, with the most value for in vivo use being beyond the 630 nm wavelength, because the absorption of light sharply decreases. Whole-body in vivo fluorescence imaging has not yet reached a state of maturity that allows its routine use in the scope of large-scale pre-clinical studies. This is in part due to an incomplete understanding of what the actual fundamental capabilities and limitations of this imaging modality are. However, progress is continuously being made in research laboratories pushing the limits of the approach to consistently improve its performance in terms of spatial resolution, sensitivity and quantification. This paper reviews this imaging technology with a particular emphasis on its potential uses and limitations, the required instrumentation, and the possible imaging geometries and applications. A detailed account of the main commercially available systems is provided as well as some perspective relating to the future of the technology development. Although the vast majority of applications of in vivo small animal imaging are based on epi-illumination planar imaging, the future success of the method relies heavily on the design of novel imaging systems based on state-of-the-art optical technology used in conjunction with high spatial resolution structural modalities such as MRI, CT or ultrasound.

Abstract: In vivo imaging of treatment responses at the molecular level could have a significant impact on the speed of drug discovery and ultimately lead to personalized medicine. Strong interest has been shown in developing quantitative fluorescence-based technologies with good molecular specificity and sensitivity for noninvasive 3D imaging through tissues and whole animals. We show herein that tumor response to chemotherapy can be accurately resolved by fluorescence molecular tomography (FMT) with a phosphatidylserine-sensing fluorescent probe based on modified annexins. We observed at least a 10-fold increase of fluorochrome concentration in cyclophosphamide-sensitive tumors and a 7-fold increase of resistant tumors compared with control studies. FMT is an optical imaging technique developed to overcome limitations of commonly used planar illumination methods and demonstrates higher quantification accuracy validated by histology. It is further shown that a 3-fold variation in background absorption heterogeneity may yield 100% errors in planar imaging but only 20% error in FMT, thus confirming tomographic imaging as a preferred tool for quantitative investigations of fluorescent probes in tissues. Tomographic approaches are found essential for small-animal optical imaging and are potentially well suited for clinical drug development and monitoring.

Abstract: Magnetic resonance imaging apparatus and methods, including providing selective radio frequency pulses including pairs of pulses, which define planes with an intersection that defines an imaging volume The imaging volumes are part of a first image surface passing through the sample and having a spatial orientation that differs from the spatial orientation of the planes The method further includes providing magnetic diffusion gradients in the sample which are associated with at least a subset of the volumes, and acquiring a series of nuclear magnetic resonance echo signals resulting from the intersection, with at least a subset of the echo signals being responsive to the gradients The signals are processed to obtain an image that includes lines corresponding to the imaging volumes